Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

Completed · Phase 3

Conditions studied: Osteoporosis Postmenopausal

In brief

To confirm the non-inferiority of 75 mg risedronate tablets taken on 2 consecutive days per month as compared to 5 mg risedronate tablets taken daily in increasing bone mass in lumbar spine in postmenopausal women with osteoporosis. To confirm the efficacy of 75 mg risedronate tablets taken on 2 consecutive days per month in postmenopausal women with osteoporosis in increasing bone mass in proximal femur, femoral neck and femoral trochanter and decreasing bone resorption. To confirm general safety of 75 mg risedronate tablets taken on 2 consecutive days per month as compared to 5 mg risedronate taken daily.

Key facts

Study ID

NCT00358176

Run by

Sanofi

People needed

1231

Starts

2004-07-01

Expected to finish

2007-03-01

Last updated by the study team

2009-12-15

Who can join

Age: 50 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Subjects meeting all of the following criteria were considered for enrollment into the study :
• ·Ambulatory, healthy postmenopausal women with :
• Natural menopause and more than 5 years after their last menstrual period.
• Or surgical menopause and more than 5 years after surgery (blood hormone tests required for subjects less than 65 years of age who had uterus removed without removal of ovaries at time of surgery).
• Osteoporosis (lumbar spine T-score more than 2.5 SD below the mean value in normal young women or more than 2.0 SD below the mean value in normal young women and at least 1 fracture of a vertebra (thoracic-lumbar T4-L4)).

You may not qualify if…

• Subjects with any of the following criteria were not considered for enrollment into the study :
• ·Women who have received hormone replacement therapy (with estrogen by mouth and/or progestogen and/or androgen) or raloxifene, or other bone active drugs, such as calcitonin, calcitriol/calcidiol/alfacalcidol, parathyroid hormone or any bisphosphonate within 3 months before first dose of study medication.

Where it is running

• Sanofi-Aventis — Bridgewater, New Jersey, United States
• Sanofi-Aventis — San Isidro, Argentina
• Sanofi-Aventis — Macquarie Park, Australia
• Sanofi-Aventis — Laval, Canada
• Sanofi-Aventis — Prague, Czechia
• Sanofi-Aventis — Paris, France
• Sanofi-Aventis — Beirut, Lebanon
• Sanofi-Aventis — Warsaw, Poland
• Sanofi-Aventis — Midrand, South Africa
• Sanofi-Aventis — Istanbul, Turkey (Türkiye)
• Sanofi-Aventis — Guildford Surrey, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.